Positron-emission tomography in gynaecologic malignancies

Anna Margherita Maffione, Michela Piva, Charoula Stavroula Tsamita, Cristina Nanni, Paolo Castellucci, Valentina Ambrosini, Egesta Lopci, Alessandra Musto, Lucia Rampin, Gaia Grassetto, Maria Cristina Marzola, Arianna Massaro, Elena Cracco, Adil Al-Nahhas, Stefano Fanti, Domenico Rubello

Research output: Contribution to journalArticlepeer-review


Introduction: The role of 18F-FDG PET in the management of gynaecologic malignancies remains unclear mainly due to the failure of clinicians to appreciate the significance of this imaging tool. However, this under utilisation is being actively re-addressed with a large number of reviews and studies, particularly in the last few years. Methods and Results: PET has been shown to have high sensitivity and specificity in the evaluation of relapse and nodal disease in cervical cancer, while other uses such as staging and monitoring response to therapies being under further investigation. Similarly, promising results have been published in the use of PET in patients affected by endometrial cancer and uterine sarcomas for detecting lymph nodes metastasis and recurrent disease. In ovarian cancer, PET appears to have a great potential in staging and assessment of disease relapse. An important utility of PET in gynaecologic tumours, which is shared with a large number of other malignancies, is its value in positively changing the patients' management. Conclusion: The surge in studies using PET in gynaecological malignancies is in its early stages, and further studies are required to optimise the role of PET in these conditions.

Original languageEnglish
Pages (from-to)521-528
Number of pages8
JournalArchives of Gynecology and Obstetrics
Issue number4
Publication statusPublished - Oct 2009


  • Cervical cancer
  • Endometrial cancer
  • Gynaecologic malignancy
  • Oncology
  • Ovarian cancer
  • PET/CT

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Positron-emission tomography in gynaecologic malignancies'. Together they form a unique fingerprint.

Cite this